A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed…
With volatility near a 12-month low, the premium that SPYI, JEPQ, and GPIQ convert into monthly cash has shrunk, and a $500,000 stake in the wrong fund now exposes a flaw most investors discover…
A seven-week trial against Meta carries a headline damages figure that most investors are anchoring to for the wrong reasons, and the part of the case that could actually reshape the apps barely makes…
Not all mortgage REITs offering double-digit yields are running the same play, and confusing one for another right now carries real consequences for income investors.
Home Depot's stock sits well below its 52-week high after a rough stretch, but something in the latest earnings report caught analysts off guard and shifted the outlook in a meaningful way.
Three NEOS ETFs are structuring their payouts in a way that leaves the IRS with far less than usual, and the approach has nothing to do with tax shelters or complicated account types. The…
XRP broke below $1 for the first time in nearly two years, and the data behind the crash points to a cause that has nothing to do with holders selling. The real pressure source…
Some of Wall Street's most legendary hedge fund managers quietly moved into SpaceX last quarter, but the size of those bets tells a story the headlines are missing.
A small category of bond funds terminates on a fixed date and hands cash back to investors, behaving nothing like a typical ETF, and right now three of them sit on a yield curve…
A Chinese robotics IPO just attracted demand so extreme it raises a question every investor in physical AI needs to answer: are the stocks pricing in a revolution that still runs on manufacturing timelines,…
A tiny optical computing stock sits at the bleeding edge of AI infrastructure, trading at a fraction of its recent highs while holding a balance sheet that just eliminated its biggest existential risk. Whether…
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
A five-year pause on Social Security garnishment for seniors with old student loans is about to end, and a new Senate bill is the only thing standing between hundreds of thousands of retirees and…
Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but Wall Street analysts spotted opportunity and danger in names like Baidu, Klarna, Honeywell Aerospace, and Dollar Tree that traders need…
With the 30-year Treasury sitting above 5%, a fat dividend yield stops being a reward and starts being a warning sign. Five popular income stocks are failing a coverage checklist that separates genuine payouts…
